Serum CEA Level Change and Its Significance Before and after Gefitinib Therapy on Patients with Advanced Non-small Cell Lung Cancer |
Qin, Hai-Feng
(Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science)
Qu, Li-Li (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science) Liu, Hui (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science) Wang, Sha-Sha (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science) Gao, Hong-Jun (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science) |
1 | Sakai A, Kasahara K, Sone T (2013). Detection of EGFR T790M mutation in pericardial effusion from a non-small cell lung cancer patient with erlotinib therapy. Case Rep Oncol, 6, 15-20. DOI ScienceOn |
2 | Sechler M, Cizmic AD, Avasarala S, et al (2013). Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med, 6, 25-36. |
3 | Shrestha S, Joshi P (2012). Gefitinib monotherapy in advanced non-small-cell lung cancer: a retrospective analysis. J Nepal Med Assoc, 52, 66-71. |
4 | Sudo M, Chin TM, Mori S, et al (2013). Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemother Pharmacol, 71, 1325-34. DOI ScienceOn |
5 | Tanaka K, Hata A, Kaji R, et al (2013). Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. J Thorac Oncol, 8, 892-8. DOI ScienceOn |
6 | Tomonaga N, Nakamura Y, Yamaguchi H, et al (2013). Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer. |
7 | Wheler J, Falchook G, Tsimberidou AM, et al (2013). Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD anderson cancer center phase I population. Oncotarget, 4, 772-84. |
8 | Morabito A, Costanzo R, Rachiglio AM, et al (2013). Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. J Thorac Oncol, 8, e59-60. DOI ScienceOn |
9 | Wu C, Li F, Jiao SC (2012). Prognostic factors for survival of patients with extensive stage small cell lung cancer--a retrospective single institution analysis. Asian Pac J Cancer Prev, 13, 4959-62. 과학기술학회마을 DOI ScienceOn |
10 | Acunzo M, Romano G, Palmieri D, et al (2013). Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A, 110, 8573-8. DOI ScienceOn |
11 | Al Dayel F (2012). EGFR mutation testing in non-small cell lung cancer (NSCLC). J Infect Public Health, 5, S31-4. DOI ScienceOn |
12 | Al Zobair AA, Al Obeidy BF, Yang L, et al (2013). Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncol Rep, 29, 1524-32. |
13 | Araki T, Yashima H, Shimizu K, et al (2012). Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol, 6, 407-21. |
14 | Jeon WI, Ryu PD, Lee SY (2012). Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells. Anticancer Res, 32, 5279-84. |
15 | Aydiner A, Yildiz I, Seyidova A (2013). Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status. Asian Pac J Cancer Prev, 14, 3255-61. 과학기술학회마을 DOI ScienceOn |
16 | Chen G, Kronenberger P, Teugels E, et al (2013). Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun, 431, 623-9. DOI ScienceOn |
17 | Han Y, Wang XB, Xiao N, et al (2013). mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev, 14, 987-90. 과학기술학회마을 DOI ScienceOn |
18 | Karachaliou N, Costa C, Gimenez-Capitan A, et al (2013). BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. J Thorac Oncol, 8, 295-300. DOI ScienceOn |
19 | Lee E, Keam B, Kim DW, et al (2013). Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol, 8, 1069-74. DOI |
20 | Lee KH, Lee KY, Jeon YJ, et al (2012). Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE). Tuberc Respir Dis (Seoul), 73, 303-11. 과학기술학회마을 DOI ScienceOn |
21 | Louis RA, Rajendranath R, Ganesan P, et al (2012). First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients. Indian J Med Paediatr Oncol, 33, 146-54. DOI ScienceOn |
22 | Liang J, Qian Y, Xu D, et al (2013). Serum Tumor Markers, Hypoxia-Inducible factor- HIF- and Vascular Endothelial Growth Factor, in Patients with Non- small Cell Lung Cancer Before and after Intervention. Asian Pac J Cancer Prev, 14, 3851-4. DOI ScienceOn |
23 | Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. 과학기술학회마을 DOI ScienceOn |
24 | Lopez-Rios F, Angulo B, Gomez B, Mair D, et al (2013). Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol, 66, 381-5. DOI ScienceOn |
25 | Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. 과학기술학회마을 DOI ScienceOn |
26 | Maftouh M, Avan A, Galvani E, et al (2013). Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer. Crit Rev Oncog, 18, 317-26. DOI |